1.
Global Spread and Persistence of Dengue
by KYLE, Jennifer L
Annual review of microbiology, 2008, Vol.62 (1), p.71-92
2.
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
by Sabchareon, Arunee, Prof
The Lancet (British edition), 2012, Vol.380 (9853), p.1559-1567
3.
Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial
by Capeding, Maria Rosario, MD
The Lancet (British edition), 2014, Vol.384 (9951), p.1358-1365
4.
Protective and immunological behavior of chimeric yellow fever dengue vaccine
by Halstead, Scott B
Vaccine, 2016, Vol.34 (14), p.1643-1647
5.
Dengue viral infections
by Malavige, G N
Postgraduate Medical Journal, 2004-10, Vol.80 (948), p.588-601
6.
Dengue and dengue vectors in the WHO European region: past, present, and scenarios for the future
by Schaffner, Francis, PhD
The Lancet infectious diseases, 2014, Vol.14 (12), p.1271-1280
7.
Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses
by Guy, Bruno
Vaccine, 2009, Vol.28 (3), p.632-649
8.
Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial
by Low, Jenny G, MPH
The Lancet infectious diseases, 2014, Vol.14 (8), p.706-715
9.
Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys
by Clements, David E
Vaccine, 2010, Vol.28 (15), p.2705-2715
10.
Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects
by Guy, Bruno
Vaccine, 2008, Vol.26 (45), p.5712-5721
11.
Dengue vaccines: recent developments, ongoing challenges and current candidates
by McArthur, Monica A
Expert review of vaccines, 2013-08-01, Vol.12 (8), p.933-953
12.
13.
Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, pha...
by Osorio, Jorge E, Dr Prof
The Lancet infectious diseases, 2014, Vol.14 (9), p.830-838
14.
Dengue outlook for the World Cup in Brazil: an early warning model framework driven by real-time seasonal climate forecasts
by Lowe, Rachel, Dr
The Lancet infectious diseases, 2014, Vol.14 (7), p.619-626
15.
Long-term safety assessment of live attenuated tetravalent dengue vaccines: Deliberations from a WHO technical consultation
by Bentsi-Enchill, Adwoa D
Vaccine, 2013, Vol.31 (23), p.2603-2609
16.
Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles
by Lindow, Janet C
Vaccine, 2013, Vol.31 (33), p.3347-3352
17.
Identifying protective dengue vaccines: Guide to mastering an empirical process
by Halstead, Scott B
Vaccine, 2013, Vol.31 (41), p.4501-4507
18.
Evaluation of Dengue Virus strains for human challenge studies
by Mammen, M.P
Vaccine, 2014, Vol.32 (13), p.1488-1494
19.
Models of the impact of dengue vaccines: A review of current research and potential approaches
by Johansson, Michael A
Vaccine, 2011, Vol.29 (35), p.5860-5868
20.
A Survey of Insecticide Resistance in Aedes albopictus (Diptera: Culicidae) During a 2014 Dengue Fever Outbreak in Guangzhou, China
by Yiguan, Wang
Journal of economic entomology, 2016-12-23, Vol.110 (1), p.239-244
